Cargando…

Spinal Muscular Atrophy Biomarker Measurements from Blood Samples in a Clinical Trial of Valproic Acid in Ambulatory Adults

Background: Clinical trials of therapies for spinal muscular atrophy (SMA) that are designed to increase the expression the SMN protein ideally include careful assessment of relevant SMN biomarkers. Objective: In the SMA VALIANT trial, a recent double-blind placebo-controlled crossover study of valp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renusch, Samantha R., Harshman, Sean, Pi, Hongyang, Workman, Eileen, Wehr, Allison, Li, Xiaobai, Prior, Thomas W., Elsheikh, Bakri H., Swoboda, Kathryn J., Simard, Louise R., Kissel, John T., Battle, Daniel, Parthun, Mark R., Freitas, Michael A., Kolb, Stephen J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2015
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271431/ https://www.ncbi.nlm.nih.gov/pubmed/27858735 http://dx.doi.org/10.3233/JND-150081

Ejemplares similares

Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy
por: Swoboda, Kathryn J., et al.
Publicado: (2009)

SMA CARNI-VAL TRIAL PART II: A Prospective, Single-Armed Trial of L-Carnitine and Valproic Acid in Ambulatory Children with Spinal Muscular Atrophy
por: Kissel, John T., et al.
Publicado: (2011)

SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy
por: Swoboda, Kathryn J., et al.
Publicado: (2010)

Safety, Tolerability, and Effect of Nusinersen in Non-ambulatory Adults With Spinal Muscular Atrophy
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Electrophysiological biomarkers in spinal muscular atrophy: proof of concept
por: David Arnold, W, et al.
Publicado: (2014)

Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
por: Glascock, Jacqueline, et al.
Publicado: (2023)

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study
por: Kolb, Stephen J., et al.
Publicado: (2016)

Persistent neuromuscular junction transmission defects in adults with spinal muscular atrophy treated with nusinersen
por: Arnold, W David, et al.
Publicado: (2021)

Carrier screening for spinal muscular atrophy
por: Prior, Thomas W.
Publicado: (2008)

Ambulatory function in spinal muscular atrophy: Age-related patterns of progression
por: Montes, Jacqueline, et al.
Publicado: (2018)

Spinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance
por: Keinath, Melissa C, et al.
Publicado: (2021)

H1 histones: current perspectives and challenges
por: Harshman, Sean W., et al.
Publicado: (2013)

Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA
por: Elsheikh, Bakri, et al.
Publicado: (2021)

Update on Biomarkers in Spinal Muscular Atrophy
por: Pino, Megan G, et al.
Publicado: (2021)

Impaired kidney structure and function in spinal muscular atrophy
por: Nery, Flávia C., et al.
Publicado: (2019)

Emerging therapies and challenges in spinal muscular atrophy
por: Farrar, Michelle A., et al.
Publicado: (2017)

Increased systemic HSP70B levels in spinal muscular atrophy infants
por: Eichelberger, Eric J., et al.
Publicado: (2021)

Case of Marked Muscular Atrophy of Hands and Fore-Arms—Progressive Muscular Atrophy(?)
por: Ness, R. Barclay
Publicado: (1895)

Base editing as a genetic treatment for spinal muscular atrophy
por: Alves, Christiano R. R., et al.
Publicado: (2023)

Single-Blind, Randomized, Controlled Clinical Trial of Exercise in Ambulatory Spinal Muscular Atrophy: Why are the Results Negative?
por: Montes, Jacqueline, et al.
Publicado: (2015)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Preferences and Utilities for Treatment Attributes in Type 2 and Non-ambulatory Type 3 Spinal Muscular Atrophy in the United Kingdom
por: Lo, Siu Hing, et al.
Publicado: (2021)

Whole‐blood dysregulation of actin‐cytoskeleton pathway in adult spinal muscular atrophy patients
por: Siranosian, Jennifer J., et al.
Publicado: (2020)

Novel heterozygous truncating titin variants affecting the A‐band are associated with cardiomyopathy and myopathy/muscular dystrophy
por: Rich, Kelly A., et al.
Publicado: (2020)

Acute pancreatitis induced by valproic acid
por: Khouadja, S., et al.
Publicado: (2021)

Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial
por: Bonanno, Silvia, et al.
Publicado: (2022)

Implications of circulating neurofilaments for spinal muscular atrophy treatment early in life: A case series
por: Alves, Christiano R.R., et al.
Publicado: (2021)

Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
por: Khan, Navid, et al.
Publicado: (2019)

Amyotrophic Lateral Sclerosis and Progressive Muscular Atrophy
por: Williamson, R. T.
Publicado: (1907)

Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy
por: Alves, Christiano R. R., et al.
Publicado: (2020)

Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy
por: Al‐Zaidy, Samiah, et al.
Publicado: (2018)

Muscle contractility in spinobulbar muscular atrophy
por: Dahlqvist, Julia R., et al.
Publicado: (2019)

Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid
por: Darbar, Illora A, et al.
Publicado: (2011)

Age-Dependent Anti-migraine Effects of Valproic Acid and Topiramate in Rats
por: Huang, Pokai, et al.
Publicado: (2018)

Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening
por: Glascock, Jacqueline, et al.
Publicado: (2018)

Spinal muscular atrophy
por: D'Amico, Adele, et al.
Publicado: (2011)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omar, A.
Publicado: (1947)

Progressive Muscular Atrophy
por: Omer, M. A.
Publicado: (1949)

Muscular Atrophy and Sclerodermia
por: Nixon, J. A.
Publicado: (1903)

Cannot write session to /tmp/vufind_sessions/sess_cklaojg2cbc98gcnf3r3aqtaqv